Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab phase 3 extension in apolipoprotein E ε4 noncarrier patients with Alzheimer's disease
2009-015079-29Phase 3Completed
- Sponsor
- Wyeth
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Wyeth. Primary endpoints: Adverse events, Brain MRI scans and 6 more. Started Nov 2009; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-015079-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015079-29.